Capricor Therapeutics, Inc.
CAPR
Positions held
Your positionsCAPR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $465.69M | Enterprise value | $318.80M | Trailing P/E | — | Forward P/E | -5.42 |
| PEG | 0.38 | Price / book | 1.89 | Beta | 0.61 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -73.7% | ROA | -33.6% | Debt / equity | 0.37 |
| Current ratio | 7.35 | Free cash flow | -$89.19M | Analyst recommendation | buy | Mean target | $27.00 |
| 52w high | $40.37 | 52w low | $2.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$40.7M | -$33.9M | -$30.2M | -$24.6M | -$25.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$42.9M | -$36.8M | -$29.2M | -$26.3M | -$27.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $22.3M | $25.2M | $2.6M | — |
| Op margin | — | -191.1% | -95.6% | -1163.9% | — |
| Net income | -$105M | -$40.5M | -$22.3M | -$29.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$108M | -$42.6M | -$24.1M | -$29.7M | — |
Headline risk — review
• [CRITICAL · regulatory] Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
• [OK · fundamentals] Capricor Therapeutics Shares Rise After Upgrade From B. Riley
News
2026-10-07 · CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
2026-10-07 · Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
2026-10-01 · CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
2026-09-30 · Top Premarket Gainers
2026-09-30 · Why Did CAPR Stock Jump 20% After-Hours Today?
2026-09-23 · Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
2026-09-17 · Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
2026-09-14 · Sector Update: Healthcare Stocks Gain Late Afternoon
2026-09-14 · Capricor Therapeutics Shares Rise After Upgrade From B. Riley
2026-09-14 · B. Riley Upgrades Capricor Therapeutics to Buy From Neutral, Raises Price Target to $21 From $5
Price (daily)
Full chart · RSI · MACD · patterns